Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 3Terminated 2

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Conditions

Neoplasms 2COVID-19 2

Interventions

BNT162 Vaccine 22019-nCoV Vaccine mRNA-1273 2tocilizumab 1sotrovimab 1heterologous prime boost COVID-19 vaccination 1cilgavimab and tixagevimab drug combination 1Therapeutics 1Specimen Handling 1Sodium Chloride 1Radiotherapy 1Losartan 1Janus Kinase Inhibitors 1Ivermectin 1Interleukin-7 1Hydroxychloroquine 1HuMax-IL8 1Ad26COVS1 13-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid 111-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × COVID-19 × 2019-nCoV Vaccine mRNA-1273 × Clear all
NCT05075538 2024-01-17

I-SPARC

Jules Bordet Institute

Phase 4 Terminated
152 enrolled

COVID-19, Neoplasms

NCT04930055 2023-05-19

Immune Responses in Oncology Patients to Novel Coronavirus Vaccines (IROC)

Indiana University

Terminated
2,206 enrolled

COVID-19, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡